Myeloid Blood Cancer Treatment Market Outlook:
Myeloid Blood Cancer Treatment Market size was over USD 12.4 billion in 2024 and is estimated to reach USD 29.1 billion by the end of 2037, exhibiting a CAGR of 8.9% during the forecast period, i.e., 2025-2037. In 2025, the industry size of myeloid blood cancer treatment is estimated at USD 13.4 billion.
According to the report published by the World Health Organization, cases of chronic myeloid leukemia are rising, that already diagnosed approximately 250,500 cases worldwide. The growing cases of myeloid leukemia has created a significant demand for the market. Besides, the expansion of Medicare coverage has increased the accessibility rate and led to robust development in revenue accumulation. According to the data published by the National Institute of Health, more than USD 2 billion is contributed to advanced research on blood cancer.
The supply chain management often experiences constraints due to high demand in the global market. Small molecule required for the production of API is supplied mainly by India and China. This leads the U.S. and EU to import more than 40% of their tyrosine kinase inhibitor (TKIs). According to the report published by the U.S. Bureau of Labor Statistics, the producer price index (PPI) rose 6.9% and the consumer price index increased by 9.3% in 2024 for targeted therapies. High demand in the market, as per the data analytics, often leads to a shortage of raw material and a rise of the product. Approval timing as per the EMA fast-tracked four myeloid treatments in Europe is reduced to less than 45%, which elevated manufacturing scalability.
Myeloid Blood Cancer Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Quality healthcare: Advanced healthcare and constant initiative for development within the healthcare sector leveraged the demand for the market. According to the study of the Agency for Healthcare Research and Quality, the rate of hospitalization is reduced by 30% through the use of FLT3 inhibitors in myeloid blood cancer treatment. This has resulted in saving more than USD 1 billion in the U.S. and boosted dependency on the concerned market. The regulatory complexity that leads to a delay in the introduction of a new product is minimized through varied government strategies. For instance, EMA’s adaptive pathway limited the approval period of the drug to less than 7 months.
- Increased rate of disease prevalence: The rate of acute myeloid leukemia is high among the aged population. According to the report published by the National Cancer Institute of the U.S., the growth of acute myeloid leukemia rose approximately 2.4% annually. New cases of approximately 21,400 are registered, which raises the demand for the market in the U.S. Besides, Germany also possesses the growing trend of myeloid leukemia patients, and more than 57,000 cases have been registered in 2024. Advanced treatment and a higher rate of recovery through myeloid blood cancer treatment acted as the key factor that gained trust among the patients and led to high demand for the concerned market.
Manufacturing Strategies to Ensure Market Expansion
The key drivers that led the top players of the market to expand globally include innovation through advanced technology, development in treatment efficacy, and ensuring better patient outcomes. For instance, Novartis focused on the introduction of targeted radiopharmaceuticals, which resulted in a sales surge of more than 260%. This expanded the company budget allocation for similar technology development and gained competitive performance in the global market. Apart from that, automation integration led Johnson & Johnson to collaborate with an AI firm to expand its drug discovery process. This helped to control the development cost and align with the market requirement.
Revenue Opportunities for Myeloid Blood Cancer Treatment Manufacturers
|
Company |
Strategy Implemented |
Projected Revenue Impact (USD) |
Implementation Year |
|
Novartis |
Targeted Radiopharmaceuticals (Pluvicto) |
+990 million |
2023 |
|
Global AML Market |
Focus on Market Growth and expansion. |
+ 1.3 billion |
2023 |
|
Johnson & Johnson |
Introduction of AI Integration in Drug Development |
+4 billion |
2023 |
|
Geron Corporation |
FDA Advisory Panel Approval for Imetelstat |
+3.3 billion |
2023 |
Key Market Dynamics for Historical Patient Growth
The myeloid blood cancer treatment market rose at a vigorous rate within the period of 2010 to 2020. The key factors that led to the historical growth of patients include an aging population, advancements in therapeutic interventions, and a growing incidence rate worldwide. Development within the diagnosis process and adoption of targeted therapy led to steady growth in the market of the U.S., Germany, China, and many other countries. For instance, the expansion of Medicare in the U.S. led to higher accessibility in the concerned market and achieved early detection. This resulted in a 34% growth of the survival rate over more than 4 years for acute myeloid leukemia patients. The market in India experienced robust growth through a higher rate of diagnosis for myeloid cancer cases in the urbanized and polluted areas.
Historical Patient Growth (2010–2020) in Key Markets
|
Country |
2010 Procedures (millions) |
2020 Procedures (millions) |
CAGR (%) |
|
U.S. |
46,000 |
69,000 |
52% |
|
Germany |
18,500 |
28,500 |
56.5% |
|
France |
12,500 |
19,500 |
58.7% |
|
Spain |
8,700 |
14.300 |
75.45% |
|
Australia |
5,200 |
9,400 |
80.7% |
|
Japan |
22,500 |
38.600 |
73.9% |
|
India |
15,700 |
48,600 |
220.6% |
|
China |
36,000 |
110,500 |
215% |
Challenges
- High cost of the treatment: The manufacturing cost of the drugs and other therapeutic devices increases, which automatically raises the treatment expense. Advanced therapies that include tyrosine kinase inhibitors (TKIs) as well as CAR T-cells are extremely high in cost due to the complex supply chain management and high demand in the market. Henceforth, the cost of the treatment becomes out of budget for the low to medium-income group of people and limits the accessibility. For instance, CAR T-cells are priced at an average of USD 400,000 for each dose, which brings barriers in medical insurance coverage. This is considered the most significant barrier to a rapid boost of the market and reducing the inequality in treatment accessibility.
Myeloid Blood Cancer Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.9% |
|
Base Year Market Size (2024) |
USD 12.4 billion |
|
Forecast Year Market Size (2037) |
USD 29.1 billion |
|
Regional Scope |
|
Myeloid Blood Cancer Treatment Market Segmentation:
Distribution Channel Segment Analysis
Based on distribution channel, the hospital pharmacies is expected to achieve a market share of 61% in 2037. As per the report placed by the American Society of Hematology, more than 70% of the therapies for Acute Myeloid Leukemia or Chronic Myeloid Leukemia require hospital admission for better infrastructure availability. This raises the access of the patient and avail the myeloid blood cancer treatment from the distribution channel of hospital pharmacies. The rise of medical coverage ensured higher accessibility for the patients, and dependence on hospital pharmacies increased. According to the report of EMA, more than 78% of the targeted therapies are provided through the hospital pharmacies.
Disease Type Segment Analysis
Based on type segment, the acute myeloid leukemia is dominant with an anticipated market share growth of 52.7% in 2037. According to the approval led by the FDA, more than 5 new FLT3/IDH inhibitors are introduced in the market in 2024. This resulted in an increase in survival scope of more than 42% according to the study of the National Cancer Institute. Government investment to elevate the myeloid blood cancer treatment, more than 80% of reimbursement assurance is ensured specifically for venetoclax combinations.
Our in-depth analysis of the global market includes the following segments:
|
Disease Type |
|
|
Therapy Class |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Myeloid Blood Cancer Treatment Market - Regional Analysis
North America Market Insights
The myeloid blood cancer treatment market in North America is the dominant region within the global platform and is projected to grow with a market share accumulation of 46% in 2037. Medical coverage for patients diagnosed with blood cancer expanded, which has elevated the rate of accessibility. The lower to medium income group of people accessed the treatment facility and leveraged the growth in the market of North America. As per the declaration of the FDA, the Orphan Drug Act is incorporated that accelerate the rate of approval for the myeloid cancer treatment. Funding allocation for better research and development in cancer treatment is leveraged by the National Institute of Health, which estimates approximately USD 2 billion, which ensured an efficient outcome.
The U.S. is addressed as the dominant region in the market of North America. It is projected to grow with a market share of 45.8% by 2037. According to the report published by the Centers for Medicare & Medicaid Services, coverage for FLT3 inhibitors elevated to 86% by Medicare Part B. The demand for the treatment with the higher coverage of Medicare boosted the market of myeloid blood cancer treatment. More than six new targeted therapies were introduced in the U.S. market, which also includes 3 CAR-T products through FDA clearance, ensuring better patient outcomes. Research and development are also backed by the fund allocation of USD 2 billion for AML research, as per the reporting of the National Institute of Health.
Asia Pacific Market Insights
Asia Pacific is the fastest-growing region in the myeloid blood cancer treatment market with a projected growth of market share growth of 20.8% by 2037. According to the report addressed by the World Health Organization, more than 45% of acute myeloid leukemia is addressed due to genetic factors and pollution. The risk of cancer within the aging population is higher, and demographic shifts in Asia Pacific have accelerated the demand for myeloid blood cancer treatment. An expansion of government-led investment for the development of healthcare infrastructure and better research and development ensured the growth of the concerned market. Insurance coverage is expanded to raise the accessibility rate of the market. As per the report of the Ministry of Health, Labor and Welfare, more than 85% of the coverage is ensured for FLT3 inhibitor expenses for the acute myeloid leukemia patients.
China is experienced with a spontaneous growth of the market and is predicted to achieve a market share of 40.5% in 2037. Patient volume rose approximately 1.7 million in 2024, which created high demand for blood cancer treatment. According to the report of the National Medical Products Administration, approval for more than 4 novel TKIs in 2024 ensured better treatment delivery ability within the concerned market. The government of China has made fund allocation for blood cancer diagnosis based on the scheme of Healthy China 2030. Growth in government expenses boosted the potential factors within the concerned market.
Key Myeloid Blood Cancer Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
A highly competitive environment is experienced within the myeloid blood cancer treatment market. The key strategies implemented to gain a competitive edge include targeted therapies, precision medicines, and the inclusion of immunotherapies. For instance, Novartis invested in the introduction of CAR T-cell therapy, whereas expansion of treatment in monoclonal antibody portfolios is performed by Pfizer to derive a competitive edge. Collaborating with the government-funded research, Takeda and Eisai achieved a strong market presence in the Asia-Pacific market. Biosimilar treatment is enhanced that provides affordable accessibility is ensured by Samsung Biologics. Acquisition, better research, and development directed the business towards innovation and business expansion within the competitive market.
Here is a list of key players operating in the global market:
|
Company Name |
Country of Origin |
Market Share (2024) |
Industry Focus |
|
Novartis AG |
Switzerland |
22.3% |
Precision medicine, CAR-T cell therapy |
|
Pfizer Inc. |
U.S. |
18.4% |
Chemotherapy, immunotherapy |
|
Bristol-Myers Squibb |
U.S. |
15.3% |
Immuno-oncology, targeted therapies |
|
F. Hoffmann-La Roche |
Switzerland |
12.5% |
Targeted therapies, immunotherapy |
|
Sanofi |
France |
8.2% |
Stem cell therapy, leukemia treatments |
|
AstraZeneca |
UK |
xx% |
Targeted therapies, combination treatments |
|
Merck & Co., Inc |
U.S. |
xx% |
Immunotherapy, monoclonal antibodies |
|
Johnson & Johnson |
U.S. |
xx% |
Hematology-focused treatments |
|
Takeda Pharmaceutical |
Japan |
xx% |
Leukemia-specific therapies |
|
Eisai Co., Ltd. |
Japan |
xx% |
Oncology drug development |
|
CSL Limited |
Australia |
xx% |
Blood cancer biologics |
|
Samsung Biologics |
South Korea |
xx% |
Biopharmaceuticals, monoclonal antibodies |
|
Celltrion |
South Korea |
xx% |
Biosimilars, targeted therapies |
|
Sun Pharmaceutical |
India |
xx% |
Generic oncology drugs, chemotherapy |
|
Dr. Reddy’s Laboratories |
India |
xx% |
Hematology-focused generics |
|
Biocon Limited |
India |
xx% |
Biosimilars, immunotherapy |
|
Bayer AG |
Germany |
xx% |
Targeted therapies, leukemia drugs |
|
Gilead Sciences |
U.S. |
xx% |
CAR-T cell therapy, immunotherapy |
|
Amgen Inc. |
U.S. |
xx% |
Biologics, hematology treatments |
Below are the areas covered for each company in the myeloid blood cancer treatment market:
Recent Developments
- In August 2024, Novartis AG received approval for Kymriah as an expansion in CAR-T therapy. The key product enables the business to increase its market share by 13%.
- In March 2024, Pfizer Inc. introduced its new product, Besponsa, which is based on a new formulation for acute myeloid leukemia. Increased rate of responses by 16% is addressed within the patient and resulted in a quick recovery.
Author Credits: Radhika Pawar
- Report ID: 3023
- Published Date: Jun 19, 2025
- Report Format: PDF, PPT
